The Vanguard Group Discloses Position in Avadel Pharmaceuticals

The Vanguard Group, Inc. has filed a disclosure under Form 8.3 with the Irish Takeover Panel concerning its interests in Avadel Pharmaceuticals plc. The disclosure was made for securities worth over 1% of Avadel, according to the Irish Takeover Panel Act, 1997, and Takeover Rules, 2022.

As of November 12, 2025, Vanguard owns 5,524,254 ordinary shares, representing 5.67% of Avadel's relevant securities. Additionally, Vanguard purchased 711 ordinary shares at a price of 19.15 USD per unit. There were no cash-settled or stock-settled derivatives reported.

Vanguard reported no indemnity or other deal arrangements, nor any agreements relating to options or derivative voting rights. No Supplemental Form 8 was attached, indicating straightforward, non-complex holdings.